PharmExec
JULY 10, 2023
Join five industry leaders as they unpack the transformative potential of artificial intelligence in the pharmaceutical industry, offering insights into real-world applications and the future of life sciences marketing in an era shaped by rapid technological evolution.
Fierce Pharma
JULY 11, 2023
Caught in a litigation crossfire, Moderna has reportedly opened two new fronts in its COVID-19 vaccine patent war with Pfizer and BioNTech. | Moderna has lodged two new lawsuits at the High Court in Dublin, Ireland, and the Brussels Commercial Court in Belgium, Juve Patent first reported. This adds to a complex web of ongoing mRNA patent litigation.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MedCity News
JULY 11, 2023
There are three key areas of the healthcare sector where generative AI is booming the most — in terms of both venture capital funding and the development of innovative technology — according to Anjalika Komatireddy, an analyst at CB Insights. During a recent webinar, she discussed the generative AI activity occurring in these three areas: care delivery and navigation, digital therapeutics and drug discovery.
Copyright Clearance Center
JULY 14, 2023
Copyright infringement lawsuits from authors and artists against creators of Generative AI software are mounting.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
European Pharmaceutical Review
JULY 13, 2023
In EPR’s Future of Bio/Pharmaceutical Analysis online summit last month, Lonza’s Associate Director of R&D discussed the benefits and challenges of using process analytical technology (PAT) in biologics manufacturing. The CDMO’s Carrie Mason shared that PAT, “takes a little bit more time and more effort and more capital to set up in the beginning, but once you get it up and running it’s very continuous and it should continue to provide results for a long time”.
Fierce Pharma
JULY 10, 2023
Two cases of suicidal thoughts and one case of self-harm from users in Iceland of Novo Nordisk’s diabetes and obesity drugs have prompted the European Medicines Agency (EMA) to review the blockbust | Two cases of suicidal thoughts and one case of self-harm from users in Iceland of Novo Nordisk’s diabetes and obesity drugs have prompted the European Medicines Agency (EMA) to review the blockbuster products.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
Copyright Clearance Center
JULY 13, 2023
After introducing The State of Scholarly Metadata: 2023 interactive report this April at the London Book Fair, we have continued to facilitate conversations about the importance of quality metadata with those in scholarly communications.
PM360
JULY 13, 2023
PM360 asked six CEOs at companies developing cancer treatments to provide an update on the latest and most exciting breakthroughs in their respective areas of expertise including: antibody-drug conjugates, CAR-T immunotherapies, cytokine-based therapy, mRNA/epigenetics, precision immuno-oncology, and small molecules. Dan O’Connor Most Exciting Development Within Your Area of Cancer Treatments The most exciting development within the antibody-drug conjugate (ADC) space is site-specific conjugatio
Fierce Pharma
JULY 10, 2023
Just days after sewing up a pair of $897 million deals with Pfizer, Samsung Biologics has added a few hundred million dollars more to its partnership cash pile—this time courtesy of an expanded pac | Samsung Biologics said in a Monday regulatory filing that it’s inked a $390.9 million deal to help crank out Novartis drugs. The latest production pact builds on an earlier tie-up worth $81 million.
MedCity News
JULY 11, 2023
HCA Healthcare recently suffered a data breach affecting 1,038 hospitals and physician clinics across 20 states. The health system said hackers stole data from an external data storage location “exclusively used to automate the formatting of email messages.” It also said that the incident has not caused any disruption to HCA’s daily operations or the services it provides to patients.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
European Pharmaceutical Review
JULY 14, 2023
A report by Research and Markets has shown that at 35 percent, Europe has the largest share of the global aseptic fill finish services market at present. At 68 percent, the small molecules sector currently holds the largest share in the overall market. This trend is unlikely to change during the forecast period, the authors noted. Since there is a growing demand for pharmaceutical and biopharmaceutical drug products, a higher capacity for production of therapies is required, alongside their corr
PM360
JULY 13, 2023
“Drugs don’t work in patients who don’t take them,” C. Everett Koop, MD, U.S. Surgeon General, said in 1985. Novartis’ analysis of claims data from Nov. 2020 to Oct. 2021 revealed that roughly one in four prescriptions were never filled. 1 In addition, of patients who began therapy, more than 70% were no longer on their prescribed medication after 12 months. 1 Patients may discontinue if they cannot afford their out-of-pocket costs even with insurance coverage due to side effects or lack of perc
Fierce Pharma
JULY 10, 2023
After a Delaware federal court ruled a Novartis combination patent on big-selling cardiovascular drug Entresto is invalid, the company pledged to continue its efforts to block generics with an appe | After a Delaware district court ruled a 2025 Entresto combination patent is invalid, Novartis will head to the U.S. Court of Appeals for the Federal Circuit in an effort to reverse the decision.
MedCity News
JULY 9, 2023
Neko Health recently raised €60 million (about $65.8 million) in Series A financing. The Stockholm-based startup’s medical scanning technology aims to conveniently and affordably collect extensive health data to aid doctors in catching diseases early. The company’s scan takes about 10 minutes and costs €250 (about $275).
Pharma Marketing Network
JULY 13, 2023
When it comes to marketing your pharma business on Facebook, you may be wondering whether you should boost a post or create an ad. Both have their own advantages and disadvantages, so it’s important to choose the right option for your needs. Boosting a post is a quick and easy way to get more exposure for your content. When you boost a post, you’re essentially paying to increase its reach and visibility.
Clarivate
JULY 12, 2023
Clarivate provides researchers with a more holistic and comprehensive view of the scholarly landscape within a single platform with the integration of discovery of dissertation and thesis metadata records sourced from ProQuest Dissertations & Theses Global In an era where access to reliable and comprehensive research materials is crucial, Clarivate has taken a significant step towards enhancing the research experience.
Fierce Pharma
JULY 10, 2023
Angling for greater independence, it appears the time has come for WuXi’s bioconjugation offspring to leave the nest. | WuXi Biologics has unveiled a proposed spinoff and separate listing of WuXi XDC Cayman—a joint venture between WuXi Bio and WuXi STA bred to tackle contract research, development and manufacturing of bioconjugates, including antibody-drug conjugates, antibodies and other biologic intermediates.
MedCity News
JULY 9, 2023
A partial clinical trial hold has been lifted from cancer drug emavusertib and Curis has selected a dose to use in Phase 2 testing. The small molecule is being developed as a potential treatment for blood cancers.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
European Pharmaceutical Review
JULY 12, 2023
Integrated safety analysis from five prospective clinical trials for the first and only single-dose, US Food and Drug Administration (FDA)-approved microbiome -based treatment to prevent recurrent Clostridioides difficile ( C. diff ) infection after antibiotic treatment, has been published in Therapeutic Advances in Gastroenterology. The analysis is the largest safety evaluation to date of any microbiota-based live biotherapeutic.
PharmaVoice
JULY 12, 2023
A new psychedelic guidance from the agency gives a clue into how it could analyze drugs in the space, but industry leaders are eager for more.
Fierce Pharma
JULY 14, 2023
As Johnson & Johnson awaits a decision on its second attempt to resolve talc lawsuits through a bankruptcy ploy, the company is attempting another legal tactic to free itself from those liabili | As Johnson & Johnson awaits a decision on its second attempt to resolve talc lawsuits through a bankruptcy ploy, the company is attempting another legal tactic to help free itself from those liabilities—suing doctors who say that its iconic baby powder can cause cancer.
MedCity News
JULY 14, 2023
Inflammation and immunology biotech Apogee Therapeutics and Sagimet Biosciences, a company developing a drug for the fatty liver disease NASH, are the latest biotech companies to join the public markets. Both companies upsized their IPOs, raising cash for clinical trials.
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
European Pharmaceutical Review
JULY 12, 2023
The first conjugate vaccine to protect against the five predominant causes of meningococcal meningitis in Africa, has been prequalified by the World Health Organization (WHO). MenFive ® has been developed through a 13-year collaboration between the world’s largest vaccine manufacturer Serum Institute of India Pvt. Ltd. (SIIPL) and PATH, with funding from the UK government.
Pharma Marketing Network
JULY 13, 2023
Facebook ads come in a variety of formats, each with its own strengths and weaknesses. The best format for your ad will depend on your goals and your target audience. Here is a brief overview of the most popular Facebook ad formats: ● Single image ad: This is a simple and effective format that can be used to promote a product, service, or event. The image should be high-quality and eye-catching, and the text should be clear and concise. ● Video ad: Videos are a great way to tell a story or show
Fierce Pharma
JULY 14, 2023
The potentially curative promise of gene therapies often carries a steep price tag. | The potentially curative promise of gene therapies often carries a steep price tag. But for a pair of personalized medicine prospects in sickle cell disease (SCD), the cost could be worth it, at least as far as ICER is concerned.
MedCity News
JULY 14, 2023
For those unfamiliar with the CPAP recall situation in question, imagine if one-third of all cars on the road were suddenly recalled for potentially life-threatening issues. Now imagine that in the aforementioned hypothetical automobile recall, the media dedicated its energy almost entirely to reporting on the worsening problem without making viewers aware of potential solutions.
Advertiser: ZoomInfo
Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr
European Pharmaceutical Review
JULY 13, 2023
The field of immunotherapy is constantly evolving with the ultimate goal to develop new treatments that help the body’s immune system fight cancer. Immune cells, such as T cells and natural killer (NK) cells, have the inherent ability to combat diseases, including cancer, but are often inhibited by the body’s own suppressive mechanisms. Cancer immunotherapies such as checkpoint inhibitors (CPIs) were designed to counteract these.
PM360
JULY 13, 2023
A 2019 study published in the Journal of Medical Internet Research mHealth and uHealth found 704 apps related to medication adherence available from Apple (443) and Android (261). And that was four years ago! I imagine anyone willing to count the apps available today would find even more. And yet, the issue of medication nonadherence persists to this day—but it is clearly not for a lack of trying.
Fierce Pharma
JULY 13, 2023
With the multiple sclerosis market growing rapidly—from $18.9 billion in 2020 to a projec | A phase 3 study has shown that a new, subcutaneous version of Roche's Ocrevus has proven to be non-inferior to the current infused treatment as measured by the level of drug in the blood, 12 weeks after administration. An approval for the injected version would allow patients to receive treatment in 10 minutes as opposed to four hours, every six months.
MedCity News
JULY 12, 2023
The invention of 3D visualization software and virtual dissection tables have revolutionized how we teach and explore human anatomy.
Expert insights. Personalized for you.
119 
Let's personalize your content